Response Pharmaceuticals
Response Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for weight management and metabolic health, especially targeting high-need populations such as those on antipsychotic medications. Their mission is to help patients combat weight gain and metabolic dysregulation associated with mental health treatments, aiming to improve adherence and health outcomes.
Industries
Nr. of Employees
small (1-50)
Response Pharmaceuticals
1104 West Broad Street #1064, Falls Church, VA 22046
Products
RDX-002 (intestinal MTP inhibitor)
An orally administered, gut-specific small-molecule inhibitor of microsomal triglyceride transfer protein (MTP) designed to reduce intestinal lipid absorption and lower postprandial triglycerides, LDL-C and body weight without systemic bioavailability.
RDX-002 (intestinal MTP inhibitor)
An orally administered, gut-specific small-molecule inhibitor of microsomal triglyceride transfer protein (MTP) designed to reduce intestinal lipid absorption and lower postprandial triglycerides, LDL-C and body weight without systemic bioavailability.
Services
Sponsorship and execution of Phase 1b and Phase 2 clinical trials to evaluate safety, pharmacodynamics, and efficacy of lead small-molecule candidates in metabolic and weight-management indications.
Sponsorship and execution of Phase 1b and Phase 2 clinical trials to evaluate safety, pharmacodynamics, and efficacy of lead small-molecule candidates in metabolic and weight-management indications.
Expertise Areas
- Clinical trial management for metabolic indications
- Small-molecule discovery and medicinal chemistry
- Translational pharmacology and biomarker development
- CMC and API scale-up process development
Key Technologies
- Small-molecule therapeutics
- Enterocytic microsomal triglyceride transfer protein (MTP) inhibition
- ADME and pharmacokinetics assessment
- Postprandial triglyceride AUC measurement
News & Updates
Response Pharmaceuticals announced early completion of enrollment for a Phase 2 study evaluating RDX-002 in patients discontinuing GLP-1 agonists.
Response Pharmaceuticals announced the enrollment of the first patients in a Phase 2 study of RDX-002 in patients discontinuing GLP-1 agonists.
Response Pharmaceuticals announced that their drug candidate RDX-002 achieved its primary endpoint in a Phase 1b trial for AIWG.
Response Pharmaceuticals announced the successful completion of a Phase 1B clinical trial for RDX-002.
Response Pharmaceuticals closed an $8 million Series A financing round to fund clinical trials.
Response Pharmaceuticals announced early completion of enrollment for a Phase 2 study evaluating RDX-002 in patients discontinuing GLP-1 agonists.
Response Pharmaceuticals announced the enrollment of the first patients in a Phase 2 study of RDX-002 in patients discontinuing GLP-1 agonists.
Response Pharmaceuticals announced that their drug candidate RDX-002 achieved its primary endpoint in a Phase 1b trial for AIWG.
Response Pharmaceuticals announced the successful completion of a Phase 1B clinical trial for RDX-002.
Response Pharmaceuticals closed an $8 million Series A financing round to fund clinical trials.